1st Quarter 2023

1st Quarter 2023


The Clinical Board of Hemera met on January 23rd to discuss the draft Protocol of Hemera’s Prospective Observational Study.

The focus of the study is on the clinical and instrumental monitoring of 15-30 patients with a complete traumatic spinal cord injury in the sub-acute phase, involving centers in Milan, Lecco, Bergamo, Novara, and Varese.

The study will be initiated once the necessary authorizations are obtained, and the patients who can be recruited and observed have recently experienced a complete spinal cord injury, meaning they have no possibility of spontaneous recovery, within a timeframe of 3 to 8 weeks after the trauma.


Prof. Alberto Mantovani, an internationally renowned immunologist and Scientific Director of the Humanitas Clinical Institute, along with Prof. Giorgio Racagni, a renowned neuropharmacologist and former President of the International Society of Neuropsychopharmacology, are the two Italian members of Hemera’s Scientific Advisory, which is in the final stages of completion.

The Committee consists of experts in various fields who will support the team in the development of the REMaST® cellular therapy.

The Committee will also include leading international experts in the field of neurology, as well as experts in advanced cellular therapies and spinal cord injury.


The Second Annual Hemera Convention was held on Saturday, March 25th, in Lasize, amidst the beautiful backdrop of Lake Garda. Over 90 members, partners, collaborators, and interested guests attended the event, focusing on the growth prospects of our company.

The gathering was an important opportunity for the entire team to present the achieved milestones and upcoming objectives. The following individuals spoke during the meeting:

  1. Guido Fumagalli, President and Medical Director
  2. Massimo Locati, Scientific Director
  3. Ilaria Decimo, Director of Research and Development
  4. Francesco Bifari, Therapy Development Director
  5. Marco Riva, Neurosurgeon at the Humanitas Clinical Institute
  6. Giuseppe Dastoli, Director of Clinical Development
  7. Cristiana Vignoli, CEO
  8. Corrado Creston, FOF Administrator
  9. Aldo Cocchiglia, Proemera Administrator
  10. Francesco Bellò, B2 Sviluppo Administrator